# Eli Lilly and Company (LLY) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $1149.36, market value $1.02 trillion.

## Valuation
- **P/E (trailing): 38.6×** (5-yr avg 61.1×, 3-yr avg 70.2×). Eli Lilly and Company trades at 38.6× trailing earnings, well below its own five-year average of 61.1×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 24.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.25**. A PEG of 0.25 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 12.9×**. Each dollar of revenue is priced at 12.9×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 30.2×**. The shares trade at 30.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Earnings yield: 2.6%**. The inverse of the P/E: 2.6% of the price is earned each year.

## Profitability
- **Net margin: 31.7%**. 31.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 77.8%**. A 77.8% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on assets: 23.7%**. Each dollar of assets produces 23.7% of profit.

## Growth
- **Revenue growth (1 yr): 44.7%** (3-yr 31.7%/yr, 5-yr 21.6%/yr). Revenue grew 44.7% over the last year, against 21.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 96.0%** (3-yr 49.3%/yr, 5-yr 27.6%/yr). Earnings per share rose 96.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.60**. Debt is 1.60 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.60%** ($6.46 per share, trailing). Eli Lilly and Company yields 0.60%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 26%**. 26% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 15.2%/yr** (1-yr 15.4%). The dividend has compounded at 15.2% a year over five years, doubling roughly every 5 years at that pace.

## Analyst view
- **Analyst consensus: buy** (29 analysts). 29 analysts cover Eli Lilly and Company; the consensus is buy, with an average price target of $1315.56 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 55.5%** (YTD 7.3%, 3-mo 1.6%). The shares are up 55.5% over twelve months including dividends.
- **From 52-week high: -11.1%** (61.4% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 0.34** (volatility 36%). Beta of 0.34 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LLY · Page: https://foliofundamentals.com/stocks/lly

Not investment advice.